5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Matthew Fust Biography and Net Worth

Director of Crinetics Pharmaceuticals

Mr. Fust joined Ultragenyx as a board member in January 2014. He is a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. from January 2009 until January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer of Jazz Pharmaceuticals, Inc. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust serves on the board of directors of Atara Biotherapeutics, Inc., and Crinetics Pharmaceuticals, Inc. Mr. Fust received his B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

What is Matthew K. Fust's net worth?: The estimated net worth of Matthew K. Fust is at least $952,750.40 as of March 20th, 2024. Mr. Fust owns 18,536 shares of Crinetics Pharmaceuticals stock worth more than $952,750 as of May 20th. This net worth evaluation does not reflect any other investments that Mr. Fust may own. Learn More about Matthew K. Fust's net worth.
How do I contact Matthew K. Fust?: The corporate mailing address for Mr. Fust and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Matthew K. Fust's contact information.
Has Matthew K. Fust been buying or selling shares of Crinetics Pharmaceuticals?: Matthew K. Fust has not been actively trading shares of Crinetics Pharmaceuticals over the course of the past ninety days. Most recently, Matthew K. Fust sold 60,000 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $44.14, for a transaction totalling $2,648,400.00. Following the completion of the sale, the director now directly owns 18,536 shares of the company's stock, valued at $818,179.04. Learn More on Matthew K. Fust's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), Ajay Madan (Insider), and Richard Struthers (CEO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, Crinetics Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $110,300.00. During the last year, insiders at the sold shares 24 times. They sold a total of 682,167 shares worth more than $24,699,904.25. The most recent insider tranaction occured on May, 10th when insider Stephen F Betz sold 3,000 shares worth more than $148,290.00. Insiders at Crinetics Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 5/10/2024.

Matthew K. Fust Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2024	Sell	60,000	$44.14	$2,648,400.00	18,536
7/13/2022	Sell	5,700	$20.96	$119,472.00	12,536
11/1/2021	Sell	8,954	$25.50	$228,327.00
9/8/2021	Sell	6,046	$25.50	$154,173.00	18,582
7/26/2021	Sell	5,000	$19.59	$97,950.00
7/19/2021	Sell	5,000	$19.50	$97,500.00	17,536
7/12/2021	Sell	5,000	$20.71	$103,550.00
12/16/2019	Sell	3,500	$22.50	$78,750.00	16,036

Matthew K. Fust Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $51.40

$50.50

$52.03

50 Day Range

MA: $45.23

$37.93

$51.91

2 Week Range

Now: $51.40

$15.76

$52.03

Volume

635,200 shs

Average Volume

787,958 shs

Market Capitalization

$4.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Urgent Nvidia Warning

From Altimetry | Ad

Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.

Click here to access…